Tromsø based ArcticZymes AS, a subsidiary of ArcticZymes Technologies, has entered into a supply and distribution agreement with precision medicine company Jiangsu Simcere Diagnostics, Nanjing, China.
“This is just the beginning of a long-term relationship together where ArcticZymes’ novel enzyme technologies and scientific competence will aid Simcere Diagnostics in marketing best in class sequencing technologies. The agreement marks the first step for ArcticZymes in becoming a long-term supplier of its enzymes to commercial partners in China,” says Jethro Holter, CEO, ArcticZymes Technologies ASA.
The nuclease supplied by ArcticZymes plays a key role in the removal of host DNA from the sample
The agreement concerns the supply of Heat-Labile Salt Active Nuclease (HL-SAN) to be used in the development and manufacturing of Simcere’s sequencing assays. HL-SAN is a critical component of Simcere Diagnostics’ infectious disease metagenomic assays. In particular, the nuclease supplied by ArcticZymes plays a key role in the removal of host DNA from the sample. This results in a streamlined and efficient sample preparation process that reduces background noise from the assay, states the company.
Simcere has three R&D centers including Boston in the United States and focuses on oncology, central nervous system disease, and autoimmune disease therapeutic and diagnostic areas with a diverse portfolio of products.
Based in Northern Norway
ArcticZymes Technologies has a long history dating back to the late 1980s.
Based in Tromsø, Northern Norway, the company uses access to the marine Arctic to identify new cold-adapted enzymes for use in molecular research, in vitro diagnostics and therapeutics.
Photo of Jethro Holter, CEO, ArcticZymes Technologies ASA